TY - JOUR T1 - MMP-3 serum levels and <em>MMP3</em> -1171insA promoter polymorphism in patients with COPD JF - European Respiratory Journal JO - Eur Respir J VL - 44 IS - Suppl 58 SP - P3828 AU - Dimo Dimov AU - Tanya Tacheva AU - Mateusz Kurzawski AU - Vasil Dimitrov AU - Marek Drozdzik AU - Tatyana Vlaykova Y1 - 2014/09/01 UR - http://erj.ersjournals.com/content/44/Suppl_58/P3828.abstract N2 - The aim of the current study was to elucidate the possible effect of the insertion/deletion promoter polymorphism at position -1171 in MMP3 gene (-1171 5A&gt;6A, ) on the risk for COPD and on the serum levels of the enzyme and to explore the association of serum enzyme concentration with clinical parameters of the disease. We genotyped for MMP3 -1171insA (5A&gt;6A) 162 patients with COPD and 172 control individuals using PCR-RFLP. The serum levels of MMP3 were measured by ELISA method. The genotype and allele frequencies of MMP3 -1171 5A&gt;6A did not show significant differences between patients and controls (p=0.553). However, the serum levels of MMP3 were significantly higher in the patients (9.90± 7.03 ng/ml) than in controls (4.99± 3.82 ng/ml, p=0.004). The patients who carry 6A/6A genotype had higher serum MMP-3 levels than the carriers of other genotypes (6A/6A- 13.54±5.64 ng/ml vs. 5A/6A- 9.30±7.11 ng/ml, p=0.029; vs. 5A/5A- 5.20±6.07 ng/ml, p=0.001). Moreover, MMP-3 serum levels were significantly lower in patients with COPD GOLD II ( 8.41± 6.87 ng/ml) than in those with COPD GOLD III and IV (12.23± 1.41 ng/ml, p= 0,041). In addition, current (14.35±6.23 ng/ml) and ex-smokers (9.56±7.06 ng/ml) appeared to have enhanced enzyme concentration than non-smokers (7.89± 6.74, p= 0.022, ANOVA test). Based on our results we suggest that the MMP3 -1171insA promoter polymorphism does not affect the risk for COPD, but may influence the serum levels of the enzyme. Moreover, due to the obtained association of the serum MMP-3 levels with GOLD stages and smoking habits, we may propose MMP-3 as a serum biomarker for severity of the diseases and possibly to be applied for following the progression of COPD. ER -